Marjorie Brand

Marjorie Brand

Auto-generated profile, based on publicly available information

Marjorie Brand

Department of Cell and Regenerative Biology, Wisconsin Institutes for Medical Research, University of Wisconsin School of Medicine and Public Health, Carbone Cancer Center, Madison, WI, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Cell Stem Cell
Verified
Journal Article
Closed access
CPCarmen G. Palii
Carmen G. Palii
QCQian Cheng
Qian Cheng
MGMark A. Gillespie
Mark A. Gillespie
PSPaul Shannon
Paul Shannon
MMMichalina Mazurczyk
Michalina Mazurczyk
MBMarjorie Brand
Marjorie Brand

23 April 2020 in Molecular Cell
Verified
Journal Article
Closed access
MGMark A. Gillespie
Mark A. Gillespie
CPCarmen G. Palii
Carmen G. Palii
DSDaniel Sanchez-Taltavull
Daniel Sanchez-Taltavull
PSPaul Shannon
Paul Shannon
WLWilliam J.R. Longabaugh
William J.R. Longabaugh
MBMarjorie Brand
Marjorie Brand

1 August 2007 in Molecular Cell
Verified
Journal Article
Closed access
CDCelina Demers
Celina Demers
CCChandra-Prakash Chaturvedi
Chandra-Prakash Chaturvedi
JRJeffrey A. Ranish
Jeffrey A. Ranish
GJGaëtan Juban
Gaëtan Juban
PLPatrick Lai
Patrick Lai
MBMarjorie Brand
Marjorie Brand

21 December 2010 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
CPCarmen G Palii
Carmen G Palii
CPCarolina Perez‐Iratxeta
Carolina Perez‐Iratxeta
ZYZizhen Yao
Zizhen Yao
YCYi Cao
Yi Cao
FDFengtao Dai
Fengtao Dai
MBMarjorie Brand
Marjorie Brand
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

1 March 2016 in Genes & Development
Verified
Journal Article
Open access
PDF file
ABAissa Benyoucef
Aissa Benyoucef
CPCarmen G. Palii
Carmen G. Palii
CWChaochen Wang
Chaochen Wang
CPChristopher J. Porter
Christopher J. Porter
ACAlphonse Chu
Alphonse Chu
MBMarjorie Brand
Marjorie Brand
T-cell acute lymphoblastic leukemia (T-ALL) is a heterogeneous group of hematological tumors composed of distinct subtypes that vary in their genetic abnormalities, gene expression signatures, and prognoses. However, it remains unclear whether T-ALL subtypes differ at the functional level, and, as such, T-ALL treatments are uniformly applied across subtypes, leading to variable responses between patients. Here we reveal the existence of a subtype-specific epigenetic vulnerability in T-ALL by which a particular subgroup of T-ALL characterized by expression of the oncogenic transcription factor TAL1 is uniquely sensitive to variations in the dosage and activity of the histone 3 Lys27 (H3K27) demethylase UTX/KDM6A. Specifically, we identify UTX as a coactivator of TAL1 and show that it acts as a major regulator of the TAL1 leukemic gene expression program. Furthermore, we demonstrate that UTX, previously described as a tumor suppressor in T-ALL, is in fact a pro-oncogenic cofactor essential for leukemia maintenance in TAL1-positive (but not TAL1-negative) T-ALL. Exploiting this subtype-specific epigenetic vulnerability, we propose a novel therapeutic approach based on UTX inhibition through in vivo administration of an H3K27 demethylase inhibitor that efficiently kills TAL1-positive primary human leukemia. These findings provide the first opportunity to develop personalized epigenetic therapy for T-ALL patients.

21 February 2008 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
MBMarjorie Brand
Marjorie Brand
SRShravanti Rampalli
Shravanti Rampalli
CCChandra-Prakash Chaturvedi
Chandra-Prakash Chaturvedi
FDF Jeffrey Dilworth
F Jeffrey Dilworth